메뉴 건너뛰기




Volumn 140, Issue 6, 2019, Pages 443-445

Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events

Author keywords

canagliflozin; dapagliflozin; diabetes mellitus, type 2; heart failure; sodium glucose transporter 2 inhibitors

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; GLUCOSE; HEMOGLOBIN A1C; NORADRENALIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 1; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIURETIC AGENT; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SLC9A1 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85069867932     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.040909     Document Type: Article
Times cited : (50)

References (5)
  • 1
    • 85032620814 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: Proposal of a novel mechanism of action
    • Packer M, Anker SD, Butler J, Filippatos G, Zannad F, Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017 2 1025 1029. doi: 10.1001/jamacardio.2017.2275
    • (2017) JAMA Cardiol , vol.2 , pp. 1025-1029
    • Packer, M.1    Anker, S.D.2    Butler, J.3    Filippatos, G.4    Zannad, F.5
  • 4
    • 85055144358 scopus 로고    scopus 로고
    • Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study
    • Abdurrachim D, Teo XQ, Woo CC, Chan WX, Lalic J, Lam CSP, Lee PTH, Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized 13 C magnetic resonance spectroscopy study. Diabetes Obes Metab 2019 21 357 365. doi: 10.1111/dom.13536
    • (2019) Diabetes Obes Metab , vol.21 , pp. 357-365
    • Abdurrachim, D.1    Teo, X.Q.2    Woo, C.C.3    Chan, W.X.4    Lalic, J.5    Lam, C.S.P.6    Lee, P.T.H.7
  • 5
    • 85035777138 scopus 로고    scopus 로고
    • Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
    • doi: 10.1007/s00125-017-4509-7
    • Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 2018 61 722 726. doi: 10.1007/s00125-017-4509-7
    • (2018) Diabetologia , vol.61 , pp. 722-726
    • Uthman, L.1    Baartscheer, A.2    Bleijlevens, B.3    Schumacher, C.A.4    Fiolet, J.W.T.5    Koeman, A.6    Jancev, M.7    Hollmann, M.W.8    Weber, N.C.9    Coronel, R.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.